Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 80.00 | |
10 mg | In stock | $ 128.00 | |
25 mg | In stock | $ 263.00 | |
50 mg | In stock | $ 422.00 | |
100 mg | In stock | $ 628.00 |
Description | XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. |
In vitro | In A375 melanoma and T47D breast cancer cells, XY028-140(0.3 or 1 µΜ for 24h) inhibited both CDK4/6 expression and CDK4/6 activity. In T47D breast cancer cells, XY028-140(0.03, 0.1, 0.3, 1, or 3 µΜ for 11d) inhibited cancer cell proliferation in breast cancer cells[1]. |
Synonyms | XY028-140 |
Molecular Weight | 760.8 |
Formula | C39H40N10O7 |
CAS No. | 2229974-83-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (6.57 mM), Sonification and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
XY028-140 2229974-83-6 Cell Cycle/Checkpoint PROTAC CDK Ligand for E3 Ligase CDK6 CDK4 PROTACs anticancer XY028140 Cyclin dependent kinase XY-028-140 XY028 140 inhibit Inhibitor inhibitor